| 国产重组链激酶治疗急性心肌梗死临床观察 |
| |
| 引用本文： | 樊世明,柳茵,李琳,刘维军,于伊,梅峰,刘连军,王红,严鹏仲,任明,马艳梅. 国产重组链激酶治疗急性心肌梗死临床观察[J]. 青海医药杂志, 2004, 34(7): 4-5 |
| |
| 作者姓名： | 樊世明 柳茵 李琳 刘维军 于伊 梅峰 刘连军 王红 严鹏仲 任明 马艳梅 |
| |
| 作者单位： | 青海医学院附属医院心内科,810001 |
| |
| 摘 要： | 目的：观察国产重组链激酶(r-sk)对急性心肌梗死(AMI)静脉溶栓的治疗和不良反应，对其安全性和疗效做出评价。方法：所有病例均符合入选和不入选标准，予r-sk150万单位于60分钟内静滴，观察血管再通的临床指标及不良反应。结果：64例患者血管再通率为82．8％，出血发生率为9．38％，表现为胃肠道轻微出血，未经特殊处理自行消失。结论：r-sk静脉溶栓再通率高，不良反应少，为一安全有效的溶栓剂。
|
| 关 键 词： | 治疗 重组链激酶 不良反应 血管再通 静脉溶栓 急性心肌梗死 观察 国产 目的 单位 |
The Clinical Trial of China-Made Recombinant Streptokinase (r-sk) in Acute Myocardial Infarction |
| |
| Fan Shiming,LiuYin,Li Ling,Liu Weijun,Yu Yi,Mei Feng,Liu Lianjun,Wang Hong,Yan Pengzhong,Ren Ming,Ma Yanmei The Affiliate Hospital of Qinghai Medical College,Xining. The Clinical Trial of China-Made Recombinant Streptokinase (r-sk) in Acute Myocardial Infarction[J]. Qinghai Medical Journal, 2004, 34(7): 4-5 |
| |
| Authors: | Fan Shiming LiuYin Li Ling Liu Weijun Yu Yi Mei Feng Liu Lianjun Wang Hong Yan Pengzhong Ren Ming Ma Yanmei The Affiliate Hospital of Qinghai Medical College Xining |
| |
| Abstract: | Objective: The purpose of this study is to evaluate the efficacy and safety of intravenous recombinant streptokinase(r-sk), produced in China, in the treatment of acute myocardial infarction(AMI). Methods: 1.5million units of r-sk were given intravenously over 60 minutes and the clinical criteria of reperfusion were evaluated. Results: The reperfusion rate for r-sk was 82.8%, mild bleeding occurred respectively in 9.38% of patients with r-sk. Conclusion: China-made r-sk is a safe and effective thrombolytic agent. |
| |
| Keywords: | Acute myocardial infarction Streptokinase Thombolytic therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
